发布求助
文献互助 智能选刊 最新文献

Clinical and Molecular Hepatology最新文献

筛选
英文 中文
Correspondence to editorial "Metabolic health in antiviral era of chronic hepatitis B". 与社论“慢性乙型肝炎抗病毒时代的代谢健康”对应。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-05-08 DOI: 10.3350/cmh.2025.0479
Rui Huang, Mindie H Nguyen
{"title":"Correspondence to editorial \"Metabolic health in antiviral era of chronic hepatitis B\".","authors":"Rui Huang, Mindie H Nguyen","doi":"10.3350/cmh.2025.0479","DOIUrl":"https://doi.org/10.3350/cmh.2025.0479","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-infectivity of Hepatitis B Virus Under Nucleoside Analog Therapy Revealed Through Auxiliary Partial Orthotopic Liver Transplantation (APOLT). 通过辅助部分原位肝移植（APOLT）揭示核苷类似物治疗下乙型肝炎病毒的非感染性。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-05-08 DOI: 10.3350/cmh.2025.0393
Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu
{"title":"Non-infectivity of Hepatitis B Virus Under Nucleoside Analog Therapy Revealed Through Auxiliary Partial Orthotopic Liver Transplantation (APOLT).","authors":"Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu","doi":"10.3350/cmh.2025.0393","DOIUrl":"https://doi.org/10.3350/cmh.2025.0393","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence to letter to the editor on "Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway. 致编辑关于“代谢功能障碍相关脂肪变性肝病的风险分层：KASL途径”的信函。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-05-08 DOI: 10.3350/cmh.2025.0477
Hye Won Lee, Seung Up Kim
{"title":"Correspondence to letter to the editor on \"Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway.","authors":"Hye Won Lee, Seung Up Kim","doi":"10.3350/cmh.2025.0477","DOIUrl":"https://doi.org/10.3350/cmh.2025.0477","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression. 揭示TRIB3: met驱动的肝细胞癌进展的新介质。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-28 DOI: 10.3350/cmh.2025.0452
Many Sze Man Chan, Terence Kin Wah Lee
{"title":"Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression.","authors":"Many Sze Man Chan, Terence Kin Wah Lee","doi":"10.3350/cmh.2025.0452","DOIUrl":"https://doi.org/10.3350/cmh.2025.0452","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence to editorial "Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma". 与社论“靶向CD36活化早期肝细胞癌中的CD8+ T细胞”对应。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-28 DOI: 10.3350/cmh.2025.0402
Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu
{"title":"Correspondence to editorial \"Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma\".","authors":"Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu","doi":"10.3350/cmh.2025.0402","DOIUrl":"https://doi.org/10.3350/cmh.2025.0402","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence to editorial on "Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway." 与《基于分区代谢特征和致癌信号通路的肝细胞癌分子分类》社论对应。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-28 DOI: 10.3350/cmh.2025.0435
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
{"title":"Correspondence to editorial on \"Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway.\"","authors":"Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo","doi":"10.3350/cmh.2025.0435","DOIUrl":"https://doi.org/10.3350/cmh.2025.0435","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B. 2型糖尿病是核苷类药物治疗慢性乙型肝炎不良结局的关键代谢危险因素。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-28 DOI: 10.3350/cmh.2025.0430
Heejoon Jang, Won Kim
{"title":"Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B.","authors":"Heejoon Jang, Won Kim","doi":"10.3350/cmh.2025.0430","DOIUrl":"https://doi.org/10.3350/cmh.2025.0430","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RISK STRATIFICATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THE KASL PATHWAY. 代谢功能障碍相关脂肪变性肝病的风险分层：kasl途径
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-28 DOI: 10.3350/cmh.2025.0420
May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong
{"title":"RISK STRATIFICATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THE KASL PATHWAY.","authors":"May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong","doi":"10.3350/cmh.2025.0420","DOIUrl":"https://doi.org/10.3350/cmh.2025.0420","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GULP1: New Hope for Hepatocellular Carcinoma: Reply to Correspondence on "GULP1 as a Novel Biomarker in HCC". GULP1：肝细胞癌的新希望：回复关于“GULP1作为HCC的新生物标志物”的信函。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-28 DOI: 10.3350/cmh.2025.0415
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
{"title":"GULP1: New Hope for Hepatocellular Carcinoma: Reply to Correspondence on \"GULP1 as a Novel Biomarker in HCC\".","authors":"Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen","doi":"10.3350/cmh.2025.0415","DOIUrl":"https://doi.org/10.3350/cmh.2025.0415","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study. GLP-1 RA与T2D和MASLD成人肝脏和非肝脏并发症的减少：一项目标试验模拟研究
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2025-04-23 DOI: 10.3350/cmh.2024.1096
Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H Nguyen
{"title":"GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study.","authors":"Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H Nguyen","doi":"10.3350/cmh.2024.1096","DOIUrl":"https://doi.org/10.3350/cmh.2024.1096","url":null,"abstract":"<p><strong>Background/aims: </strong>Information about the association of glucagon-like peptidase 1 receptor agonist (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted a target trial emulation study to evaluate whether GLP-1RA decreases the risk of liver and non-liver outcomes.</p><p><strong>Methods: </strong>Patients with T2D and MASLD initiating GLP-1RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) were included from 2013 to 2022 in Merative™ Marketscan® Research Databases. Primary outcomes included (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Inverse probability of treatment weighting was applied to balance baseline characteristics and Cox regression models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI).</p><p><strong>Results: </strong>In the intention-to-treat design, GLP-1RA, compared with DPP-4i, had a significantly lower incidence (per 1000 person-years) of HCC (0.8 vs 1.7; HR 0.53, 95%CI 0.39-0.71), of cirrhosis (29.3 vs 32.9; HR 0.91, 95%CI 0.86-0.96), of CVD (57.2 vs 73.9; HR 0.90, 95%CI 0.86-0.95), of CKD (4.5 vs 6.8; HR 0.73, 95%CI 0.64-0.84), and of non-liver cancer (16.9 vs 22.9; HR 0.82, 95%CI 0.77-0.89). In the per-protocol design, significant inverse associations for these study outcomes still were observed, with HR 0.60-0.77.</p><p><strong>Conclusions: </strong>In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":" ","pages":""},"PeriodicalIF":14.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信